The focus of this Health Technology Assessment is evaluation of the effectiveness and safety of subcutaneous implantable cardioverter defibrillators (S-ICDs) versus transvenous (TV)-ICDs for prevention of sudden cardiac death in patients with recurrent ventricular tachycardia (VT) or ventricular fibrillation.